within Pharmacolibrary.Drugs.ATC.P;

model P01AX07
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 0.043333333333333335,
    adminDuration  = 600,
    adminMass      = 0.045,
    adminCount     = 1,
    Vd             = 0.018,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0,
    Tlag           = 0
  );

  annotation(Documentation(
    info ="<html><body><p>Trimetrexate is a dihydrofolate reductase inhibitor used historically as an antiprotozoal agent, particularly against Pneumocystis jirovecii pneumonia (PCP), primarily in immunocompromised patients such as those with HIV/AIDS. It is not widely used today and is considered an alternative therapy. The drug is administered with leucovorin to mitigate toxicity.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in adults (mean age approximately 40 years), both sexes, with HIV/AIDS, treated for PCP.</p><h4>References</h4><ol><li><p>Rogers, P, et al., &amp; Balis, FM (1988). Bioavailability of oral trimetrexate in patients with acquired immunodeficiency syndrome. <i>Antimicrobial agents and chemotherapy</i> 32(3) 324–326. DOI:<a href=&quot;https://doi.org/10.1128/AAC.32.3.324&quot;>10.1128/AAC.32.3.324</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/2966610/&quot;>https://pubmed.ncbi.nlm.nih.gov/2966610</a></p></li><li><p>Bishop, JF, et al., &amp; Friedlander, ML (1989). A phase I study of trimetrexate (NSC 352122) administered by 5-day continuous intravenous infusion. <i>Cancer chemotherapy and pharmacology</i> 24(4) 246–250. DOI:<a href=&quot;https://doi.org/10.1007/BF00257627&quot;>10.1007/BF00257627</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/2526692/&quot;>https://pubmed.ncbi.nlm.nih.gov/2526692</a></p></li><li><p>Allegra, CJ, et al., &amp; Curt, GA (1990). A phase I and pharmacokinetic study of trimetrexate using a 24-hour continuous-injection schedule. <i>Investigational new drugs</i> 8(2) 159–166. DOI:<a href=&quot;https://doi.org/10.1007/BF00177251&quot;>10.1007/BF00177251</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/2143500/&quot;>https://pubmed.ncbi.nlm.nih.gov/2143500</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end P01AX07;
